CClinicalTrials.gg
RecruitingNCT06202222IRPOLUpdated Sep 10, 2025

Interest of Intensive Postoperative Rehabilitation Following Minimally Invasive Lung Resection

An interventional study of rehabilitation in Lung Cancer, sponsored by University Hospital, Rouen. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by University Hospital, Rouen · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

For patients diagnosed with non-small cell lung cancer (NSCLC), lung resection surgery remains the gold standard for curative treatment. This scheduled operation is associated with significant morbidity, particularly in individuals with impaired cardio-respiratory function. Therefore, patient optimization is paramount. The process begins prior to surgery with preoperative rehabilitation, commonly referred to as "prehabilitation," serving as the foundation for various Enhanced Recovery After Surgery programs. The training methods employed in these programs bear similarity to rehabilitation programs designed for patients with chronic obstructive pulmonary disease (COPD).

Postoperatively, patients undergoing thoracic surgery partake in daily physiotherapy sessions, aiming to optimize the postoperative period, minimize the respiratory impact of surgery, and reduce the length of hospital stay. However, this treatment is not currently standardized and primarily involves early mobilization, including walking, and respiratory physiotherapy. Our focus is on the intensity and methods of this postoperative rehabilitation.

There is limited literature on effective early rehabilitation in the immediate postoperative period, and existing studies suggest no adverse events associated with postoperative training. Therefore, our objective is to assess whether combining endurance training with standard physiotherapy (walking and respiratory physiotherapy) enhances the functional capacity of individuals undergoing lung surgery.

02

Conditions studied

  • Lung Cancer

Browse trials for

03

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's planned enrollment of 184 is above the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

University Hospital, Rouen is the lead sponsor of 410 studies on the registry; 104 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients requiring surgery for diagnosed or undergoing diagnosis of lung cancer.
  • Patients in need of major lung resection through a minimally invasive approach.
  • Patients capable of performing the chair rise test.

Exclusion criteria

Exclusion Criteria:

- Contraindications to cyclo-ergometry: Deep vein thrombosis in a lower limb. Patients with one or both lower limbs amputated. Rheumatological pathology, trauma, or previous surgery in the lower limb, pelvis, or spine, resulting in limited joint amplitude or strict immobilization.

Dermatological conditions with severe lesions preventing prolonged sitting on a bicycle.

  • Glasgow score less than 15.
  • Patients who have not undergone pulmonary resection by minimally invasive surgery.
  • Patients hospitalized outside the thoracic surgery department before the first post-operative visit with the physiotherapist on Day 0.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
184 participants (estimated)

Study arms

  • No intervention
    standard rehabilitation
  • Experimental
    standard rehabilitation and cycloergometer

    Other: rehabilitation

Interventions

  • Otherrehabilitation

    The patient undergoes a daily session on the cycloergometer (Am3i Ergometer). The patient is instructed to pedal at a heart rate ranging from 60% to 80% of their maximum heart rate (calculated as 220 minus their age) for a duration of 20 minutes. These sessions can be conducted with oxygen therapy for patients dependent on oxygen. The sessions are maintained until the patient is discharged from the department.

06

What researchers measure

Primary outcomes

  1. Number of chair lifts at the scheduled visit 30 days after surgery

    number of chair lifts

    Time frame: 30 days after surgery

Secondary outcomes

  1. number of days between surgery and discharge patient

    Time frame: 30 days after surgery

  2. chair rise test

    Time frame: 7 days after surgery

  3. number of complication GRADE II of clavien dindo classification

    Time frame: 30 days after surgery

07

Study locations

3 of 3 sites recruiting
  • Valenciennes, Hospital
    Valenciennes, Hauts-de-France 59322, France
    Recruiting
  • CAEN, university Hospital
    Caen, Normandy 14033, France
    Recruiting
  • Rouen, University Hospital
    Rouen, Normandy 76 031, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06202222
Lead sponsor
University Hospital, Rouen
Responsible party
Sponsor
First posted
Jan 11, 2024
Start date
Sep 9, 2024
Primary completion
May 9, 2027 (estimated)
Completion
May 9, 2027 (estimated)
Last update
Sep 10, 2025

Study contacts

Jean-Marc BASTE, PhD
Contact
jean-marc.baste@chu-rouen.fr
+33 2 32 88 87 04
Fairuz BOUJIBAR, PhD
Contact
fairuz.biujibar@chu-rouen.fr
+33 2 32 88 89 90 ext. 65593

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion